<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="153089">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01973790</url>
  </required_header>
  <id_info>
    <org_study_id>Z338-01</org_study_id>
    <nct_id>NCT01973790</nct_id>
  </id_info>
  <brief_title>Phase III, Long-term, Open-label Safety Study of Z-338</brief_title>
  <official_title>A Phase III, Multicentre, Single-arm, Open-label Study to Evaluate the Long-term Safety of Z-338 in Subjects With Functional Dyspepsia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zeria Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zeria Pharmaceutical</source>
  <oversight_info>
    <authority>Belgium: Federal Agency for Medicines and Health Products, FAMHP</authority>
    <authority>Slovakia: State Institute for Drug Control</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <authority>Latvia: State Agency of Medicines</authority>
    <authority>Sweden: Medical Products Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the long-term safety of 100 mg Z-338 TID
      in European subjects with FD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase III, multicentre, single-arm, open-label study to evaluate the long-term
      safety of 100 mg Z-338 TID in subjects with FD.

      The study comprises a screening period (up to 3 weeks), a run-in period (1 week) and an
      open-label treatment period (52 weeks). Including an additional 2-week follow-up period for
      assessment of AEs, the maximum duration of a subject's participation in the study will be 58
      weeks.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">March 2016</completion_date>
  <primary_completion_date type="Anticipated">January 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>General safety endpoints</measure>
    <time_frame>up to 58 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Adverse Events, 12-lead ECGs, Laboratory variables, Vital signs, Physical examination</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To explore the efficacy</measure>
    <time_frame>up to 52 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>the use of LPDS to measure FD symptom severity and the effect of Z-338, the effect of Z-338 on the QoL in subjects with FD as measured by SF-36 survey and SF-NDI, the effect of Z-338 on work productivity in subjects with FD as measured by WPAI.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Dyspepsia</condition>
  <arm_group>
    <arm_group_label>Z-338</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100mg TID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Z-338</intervention_name>
    <description>100mg TID</description>
    <arm_group_label>Z-338</arm_group_label>
    <other_name>Acotiamide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects to provide written informed consent prior to any study procedures being
             performed

          -  Subjects with a diagnosis of FD (postprandial distress syndrome) as defined by the
             Rome III Criteria

          -  Subjects must present Postprandial Fullness or Early Satiation as the most bothersome
             symptom during the 6 months prior to informed consent.

          -  Subjects must have a normal endoscopy result within the 6 months (3 months in case of
             subjects who are Helicobacter pylori positive) prior to informed consent or during
             the screening period.

        Exclusion Criteria:

          -  Subjects on PPI(s) who are unable to discontinue PPI medication by the end of the
             screening period

          -  Subjects taking drugs that affect gut motility, gut sensitivity and/or acid secretion
             who are unable to discontinue these drugs by the end of the screening period

          -  Subjects who have received H. pylori eradication therapy during the 3 months prior to
             informed consent

          -  Subjects with confirmed organic gastrointestinal disease

          -  Subjects presenting with predominant complaints relieved by stool movements
             (irritable bowel syndrome)

          -  Subjects presenting with predominant GORD symptoms

          -  Subjects presenting with predominant complaints of chronic idiopathic nausea

          -  Subjects with Type I or Type II diabetes

          -  Subjects with body mass index (BMI) over 30 kg/m2

          -  Subjects with any condition which, in the opinion of the Investigator, makes the
             subject unsuitable for entry into the study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan Tack, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Leuven, University Hospital Gasthuisberg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zeria Pharmaceutical</last_name>
  </overall_contact>
  <location>
    <facility>
      <name>Zeria Investigative site</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zeria Investigative PI</last_name>
      <phone>+81356447053</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zeria Investigative Sites</name>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zeria Investigative PI</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zeria Investigative sites</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zeria Investigative PIs</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zeria Investigative sites</name>
      <address>
        <city>Kosice</city>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zeria Investigators</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zeria Investigative Site</name>
      <address>
        <city>Malacky</city>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zeria Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zeria Investigative Site</name>
      <address>
        <city>Martin</city>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zeria Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zeria Investigative Site</name>
      <address>
        <city>Nitra</city>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zeria Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zeria Investigative Site</name>
      <address>
        <city>Nove Zamky</city>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zeria Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zeria Investigative Site</name>
      <address>
        <city>Presov</city>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zeria Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zeria Investigative Site</name>
      <address>
        <city>Trnava</city>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zeria Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zeria Investigative Site</name>
      <address>
        <city>Gothenburg</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zeria Investigative PI</last_name>
    </contact>
    <investigator>
      <last_name>Zeria Investigative PI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zeria Investigative Sites</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zeria Investigative PIs</last_name>
    </contact>
    <investigator>
      <last_name>Zeria Investigative PI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zeria Investigative site</name>
      <address>
        <city>Barnstaple</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zeria Investigative PI</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zeria Investigative site</name>
      <address>
        <city>Bath</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zeria Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zeria Investigative Site</name>
      <address>
        <city>Leamington Spa</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zeria Investigator</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Latvia</country>
    <country>Slovakia</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <lastchanged_date>June 2, 2014</lastchanged_date>
  <firstreceived_date>October 26, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Z-338</keyword>
  <keyword>Functional Dyspepsia</keyword>
  <keyword>Postprandial Distress Syndrome</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dyspepsia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
